Loading
A phase 2 trial of nivolumab and ipilimumab in colorectal cancer, run by Odense University Hospital, now recruiting.
Immunotherapy in Patients With Early dMMR Rectal Cancer is a phase 2, interventional study registered as NCT05732389 by Odense University Hospital, with a registry enrolment figure of 39 participants, started 2023-02-01 and due to reach its primary completion in 2027-07. Interventions recorded: Nivolumab; Ipilimumab. Conditions listed: Cancer of Rectum. Primary outcome: Complete clinical response. Colorectal eligibility wording from the registry: "* Histologically verified non-metastatic rectal cancer stage 1-3". Sites: Denmark. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/